Get the Stockscreener App
5.78
1.37%
-0.08
After Hours:
5.80
0.02
+0.35%
Inovio Pharmaceuticals Inc stock is traded at $5.78, with a volume of 338.65K.
It is down -1.37% in the last 24 hours and down -19.94% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$5.86
Open:
$5.8
24h Volume:
338.65K
Relative Volume:
0.93
Market Cap:
$149.03M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-8.8923
EPS:
-0.65
Net Cash Flow:
$-124.69M
1W Performance:
-1.62%
1M Performance:
-19.94%
6M Performance:
-58.36%
1Y Performance:
+23.82%
1-Day Range:
$5.70
$6.03
1-Week Range:
$5.422
$6.04
52-Week Range:
$3.888
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
6769 MESA RIDGE RD., SAN DIEGO, PA
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing - Seeking Alpha
Inovio Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inari medical director Hoffman sells over $1.8m in company stock - Investing.com
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
INVO Bioscience (NASDAQ:INVO) Stock Price Down 1.7% - Defense World
INOVIO to Present at Upcoming Scientific Conference - Lelezard
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INOVIO to Present at Upcoming Scientific Conference - StreetInsider.com
INOVIO to Present at Upcoming Scientific Conference - Marketscreener.com
INOVIO to Present at Upcoming Scientific Conference - Kilgore News Herald
INOVIO to Present at Upcoming Scientific Conference - Yahoo Finance
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 - sharewise
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 - The Motley Fool
Page 2 | INOVIO PHARMACEUTICALS INC Trade Ideas — GETTEX:GBMB - TradingView
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Short Interest in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Rises By 9.0% - MarketBeat
Page 2 | INOVIO PHARMACEUTICAL INC Trade Ideas — DUS:GBM - TradingView
Vaccine Delivery Devices Market to Witness Huge Growth by 2031 - openPR
Infectious disease index: Summit, Novavax, Inovio post gains - BioWorld Online
INO (Inovio Pharmaceuticals) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
Inovio Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Inovio Pharmaceuticals (STU:GBM) Price-to-Owner-Earnings : (As of Aug. 18, 2024) - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) 3-Year EBITDA Growth Rate : 20.20% (As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) Other Current Liabilities : €8.05 Mil (As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) Change In Inventory : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) 3-Year EPS without NRI Gro - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) Dividend Yield % : 0.00% (As of Aug. 18, 2024) - GuruFocus.com
Price T Rowe Associates Inc. MD Sells 137,501 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Price T Rowe Associates Inc. MD Has $174,000 Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - MarketBeat
Inovio Pharmaceuticals (STU:GBM) Cash Flow for Lease Financing : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals (MEX:INO) Volatility : 86.11% (As of Aug. 18, 2024) - GuruFocus.com
Inovio Pharmaceuticals (LTS:0A43) EV-to-Revenue : 178.82 (As of Aug. 17, 2024) - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) Float Percentage Of Total Shares Outstanding : 99.13% (As of Aug. 17, 2024) - GuruFocus.com
Inovio Pharmaceuticals (FRA:GBM) Operating Cash Flow per Sh - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) Debt-to-EBITDA : -0.10 (As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals (STU:GBM) Forward Rate of Return (Ya - GuruFocus.com
INOVIO Reports Inducement Grant Under Inducement Plan - Longview News-Journal
Inovio Pharmaceuticals (FRA:GBM) GF Score : 59/100 (As of Aug. 19, 2024) - GuruFocus.com
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $33.00 by Analysts at Oppenheimer - Defense World
Inovio Pharmaceuticals enters agreement for shares sales - Investing.com
SEC Form 424B5 filed by Inovio Pharmaceuticals Inc. - Quantisnow
INOVIO Reports Q2 2024 Financial Results and Provides Business Update - MyChesCo
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):